PTC-028 (15 mg/kg; administered orally twice weekly) causes ~94% (0.169 g) reduction in tumor weight compared to the control (average tumor weight, ~3g) [1].
No obvious toxicity is noted in the animals during therapy experiments as assessed by mean body weight[1].
PTC-028 (10 mg/kg or 20mg/kg; single oral doses) is administrated to the CD-1 mice. The Cmax is reached at both dose levels 1h post dose after which plasma concentrations slowly reduce[1].
| Animal Model: | Female athymic nude mice with implanted OV90 cells[1] |
| Dosage: | 15 mg/kg |
| Administration: | Orally administered; twice weekly |
| Result: | Caused ~94% (0.169 g) reduction in tumor weight. |
| Animal Model: | Female CD-1 mice[1] |
| Dosage: | 10 mg/kg or 20mg/kg |
| Administration: | Oral administered; single dose |
| Result: | Total plasma AUC0-24h were 10.9 and 26.1 μgh/mL at doses of 10 and 20 mg/kg. The Cmax for PTC-028 at 10 and 20 mg/kg was 0.79 and 1.49 ug/mL, respectively. |
